RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
RECURSION PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.61+0.15 (+4.18%)
Close on Oct 19, 2026
- Market cap
- $1.92B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.25 (−38.40%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
RECURSION PHARMACEUTICALS, INC. saw revenue fall 15.1% to $54.86M over the twelve months to Jun 30, 2026. Free cash flow was -$352.27M.
Revenue
$54.86M
-15.1% vs. a year earlier
Operating income
-$544.01M
TTM Q2 2026
Free cash flow
-$352.27M
TTM Q2 2026
EPS, diluted
-$1.04
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.92B
- P/E ratio
- –
- Price to sales
- 35.04
- Price to book
- 2.10
- Dividend yield
- –
- Free cash flow yield
- -18.33%
Fundamentals
- Revenue
- $54.86M
- Net income
- -$518.88M
- EPS, diluted
- -$1.04
- Free cash flow
- -$352.27M
- Book value per share
- $1.72
- Diluted shares
- 532M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$54.86M-15.1% YoY
Gross profit
$1.91M
Operating income
-$544.01M
Net income
-$518.88M
EPS, diluted
-$1.04
Free cash flow
-$352.27M
Reported periodTrailing twelve months